Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.
Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial metastases (Abstract 3061).
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.
